Skip to main content
Sign in Create a free account
Varsity Tutors
Sign in

Secondary And Tertiary Resources - NAPLEX

  1. A 70-year-old man (75 kg) with chronic pain is on morphine ER 30 mg PO every 12 hours and morphine IR 15 mg PO every 6 hours PRN (uses 2 doses/day). He is opioid-tolerant and is being switched to transdermal fentanyl due to dysphagia. Labs: SCr 1.2 mg/dL, AST/ALT normal; allergies: none. Using tertiary opioid conversion references, which fentanyl patch strength is the most appropriate initial conversion (rounding conservatively for safety)?
    Answer: Fentanyl patch 25 mcg/hour This question examines tertiary opioid conversion references for switching to transdermal fentanyl in opioid-tolerant patients. The key patient-specific factor is total daily morphine equivalent dose (MME) calculation for safe, conservative conversion. First, calculate MME: morphine ER 30 mg q12h = 60 mg/day, IR 15 mg x 2 = 30 mg/day, total 90 mg/day oral morphine; using conversion tables (e.g., AHFS or CDC), 90 mg oral morphine ≈ 25-37 mcg/h fentanyl patch, rounding down to 25 mcg/h for safety. Fentanyl 12 mcg/h underestimates (for <60 mg MME); 75 mcg/h and 100 mcg/h overestimate, risking overdose. A transferable clinical pearl is to use conservative conversions with monitoring for opioid switches. Resource selection ensures safety in pain management transitions.
  2. A 58-year-old man (92 kg) presents to the ED with fever, productive cough, and shortness of breath and is diagnosed with community-acquired pneumonia requiring hospitalization (non-ICU). Medical history includes COPD and type 2 diabetes; allergies: anaphylaxis to penicillin. Current medications: metformin 1000 mg PO BID, tiotropium 2.5 mcg inhaled daily, albuterol HFA PRN. Labs: SCr 1.0 mg/dL, AST/ALT within normal limits, QTc 430 ms. Based on current IDSA/ATS community-acquired pneumonia guidelines, which empiric regimen is recommended given his severe beta-lactam allergy?
    Answer: Levofloxacin 750 mg IV/PO daily monotherapy This question tests the application of infectious disease guidelines as tertiary resources for selecting empiric antibiotic regimens in community-acquired pneumonia, emphasizing the use of IDSA/ATS guidelines for hospitalized patients. The key patient-specific factor is the history of anaphylaxis to penicillin, which necessitates avoiding beta-lactam antibiotics due to potential cross-reactivity. Levofloxacin 750 mg IV/PO daily monotherapy is the best choice per IDSA/ATS guidelines, as it provides appropriate coverage for common CAP pathogens in non-ICU settings for patients with severe beta-lactam allergies. Ceftriaxone plus azithromycin is incorrect because ceftriaxone is a cephalosporin with cross-reactivity risk in penicillin anaphylaxis, misapplying guideline recommendations for allergy assessment; ampicillin/sulbactam plus doxycycline is suboptimal as it contains a penicillin derivative, directly contraindicated; ertapenem plus azithromycin is inappropriate due to carbapenem cross-reactivity risks, overlooking allergy-specific alternatives in references. Nitrofurantoin is not indicated for pyelonephritis and lacks systemic efficacy, while doxycycline provides inadequate gram-negative coverage for this condition. A transferable clinical pearl is to always cross-reference patient allergies with guideline-endorsed regimens using resources like UpToDate or IDSA documents to ensure safe empiric therapy. Selecting appropriate tertiary resources prevents adverse events by aligning treatment with evidence-based allergy management frameworks.
  3. A 58-year-old man (weight 92 kg) presents to urgent care with dysuria and urinary frequency for 2 days and is diagnosed with acute uncomplicated cystitis; he has type 2 diabetes (A1c 7.8%), hypertension, and hyperlipidemia. Current medications: metformin ER 1000 mg PO twice daily, lisinopril 20 mg PO daily, atorvastatin 40 mg PO nightly. Allergies: trimethoprim-sulfamethoxazole (rash). Labs: serum creatinine 1.6 mg/dL (high; ref 0.7–1.3), estimated creatinine clearance 48 mL/min; aspartate aminotransferase 22 U/L, alanine aminotransferase 24 U/L. Based on current IDSA guidance and tertiary dosing references for renal impairment, which medication is recommended for empiric treatment in this patient?
    Answer: Nitrofurantoin monohydrate/macrocrystals 100 mg PO twice daily for 5 days This question tests the application of IDSA guidelines and tertiary dosing references for selecting appropriate antibiotic therapy in a patient with renal impairment. The key patient-specific factor is the reduced creatinine clearance of 48 mL/min, which requires careful consideration of drug dosing and nephrotoxicity risk. Nitrofurantoin monohydrate/macrocrystals 100 mg PO twice daily for 5 days (B) is the best choice because IDSA guidelines recommend nitrofurantoin as first-line therapy for uncomplicated cystitis, and tertiary references indicate no dose adjustment is needed for CrCl >40 mL/min (though it's contraindicated if CrCl <30 mL/min). Ciprofloxacin (A) requires dose reduction to 250-500 mg every 12-24 hours for CrCl <50 mL/min and should be reserved due to resistance concerns. Amoxicillin-clavulanate (C) is not first-line for uncomplicated cystitis and requires dose adjustment for CrCl <30 mL/min. Fosfomycin (D) is given as a single 3-gram dose, not every 48 hours for 3 doses, making this regimen incorrect according to FDA-approved labeling. The clinical pearl is that nitrofurantoin remains effective and safe in mild-to-moderate renal impairment (CrCl >40 mL/min) despite historical concerns, while fluoroquinolones require both dose adjustment and judicious use due to resistance patterns.
  4. A 66-year-old man (weight 80 kg) with heart failure with reduced ejection fraction (left ventricular ejection fraction 30%), type 2 diabetes (A1c 8.2%), and chronic kidney disease stage 3 presents for medication optimization. Current medications: carvedilol 25 mg PO twice daily, lisinopril 20 mg PO daily, furosemide 40 mg PO daily, metformin 500 mg PO twice daily, and atorvastatin 20 mg PO nightly. Allergies: none. Labs: serum creatinine 1.8 mg/dL (high), estimated glomerular filtration rate 38 mL/min/1.73 m2^2, potassium 4.6 mEq/L, AST/ALT normal. Based on current ACC/AHA/HFSA heart failure guidelines, which medication should be added to reduce heart failure hospitalization and cardiovascular mortality?
    Answer: Dapagliflozin 10 mg PO daily This question tests the application of current ACC/AHA/HFSA heart failure guidelines for medication optimization in a patient with HFrEF and comorbidities. The key patient-specific factors are the reduced ejection fraction (30%), type 2 diabetes with poor control (A1c 8.2%), and CKD stage 3 with eGFR 38 mL/min/1.73 m². Dapagliflozin 10 mg PO daily (B) is the best choice because SGLT2 inhibitors are now Class 1A recommendations in HFrEF guidelines regardless of diabetes status, providing both heart failure and glycemic benefits while being safe at eGFR ≥25 mL/min/1.73 m². Sitagliptin (A) provides glycemic control but offers no cardiovascular benefit in heart failure. Pioglitazone (C) is contraindicated in heart failure due to fluid retention risk. Verapamil (D) is a non-dihydropyridine calcium channel blocker that can worsen heart failure due to negative inotropic effects and is contraindicated in HFrEF. The clinical pearl is that SGLT2 inhibitors represent a paradigm shift in heart failure management, providing mortality benefit even in non-diabetic patients, and current guidelines emphasize their early initiation alongside traditional GDMT. Tertiary references and guidelines now position SGLT2 inhibitors as foundational therapy rather than add-on treatment.
  5. A 29-year-old woman (weight 64 kg) with epilepsy is 10 weeks pregnant and reports increasing seizure frequency after her obstetrician started folic acid 1 mg PO daily. Current medications: lamotrigine 200 mg PO twice daily, prenatal vitamin daily. Allergies: none. Labs: serum creatinine 0.7 mg/dL; AST/ALT normal; lamotrigine trough concentration last month 4 mcg/mL (previously stable at 8–10 mcg/mL). Which source provides the best evidence to guide dosing adjustment and monitoring of lamotrigine during pregnancy (pharmacokinetic changes and therapeutic drug monitoring targets)?
    Answer: Primary pharmacokinetic studies and pregnancy registries accessed via PubMed (secondary literature search) This question evaluates selecting appropriate resources for managing antiepileptic drug pharmacokinetics during pregnancy. The clinical issue is decreased lamotrigine levels during pregnancy, requiring evidence-based dosing adjustments. Primary pharmacokinetic studies and pregnancy registries accessed via PubMed (B) provide the best evidence because they contain detailed data on lamotrigine clearance changes throughout pregnancy trimesters, therapeutic drug monitoring targets, and dosing adjustment strategies based on actual patient outcomes. ACOG practice bulletin (A) focuses on nausea/vomiting management, not antiepileptic drug monitoring. FDA Orange Book (C) provides therapeutic equivalence data but not pregnancy-specific pharmacokinetic information. USP-NF monograph (D) provides drug standards but lacks clinical pregnancy management guidance. The key principle is that pregnancy significantly alters lamotrigine pharmacokinetics due to increased glucuronidation, often requiring 2-3 fold dose increases to maintain therapeutic levels. Secondary literature searches provide access to specialized pregnancy registries and pharmacokinetic studies that tertiary resources may not fully capture. This evidence supports proactive dose adjustments and increased monitoring frequency during pregnancy to prevent seizure breakthrough while minimizing fetal exposure.
  6. A 59-year-old man (90 kg) is admitted with acute coronary syndrome and is started on ticagrelor 90 mg PO BID plus aspirin 81 mg PO daily. He has chronic GERD treated with omeprazole 20 mg PO daily. Labs: SCr 1.0 mg/dL, AST/ALT normal; allergies: none. Which secondary resource would best verify whether omeprazole reduces antiplatelet efficacy for ticagrelor (compared with clopidogrel) and guide whether a change is needed?
    Answer: A drug interaction database (e.g., Lexicomp/Micromedex) to assess evidence for ticagrelor–PPI interactions This question evaluates secondary interaction resources for antiplatelet efficacy with PPIs. The key patient-specific factor is ticagrelor with omeprazole, but unlike clopidogrel, ticagrelor is not significantly affected by CYP2C19 inhibition from PPIs. A drug interaction database like Lexicomp/Micromedex is the best choice, confirming minimal interaction and no change needed based on evidence. Sanford Guide is for antimicrobials, irrelevant; USP <797> for compounding, not applicable; Orange Book for generics, misapplying. A transferable clinical pearl is to verify interactions distinguishing between P2Y12 inhibitors. Resource use ensures effective post-ACS therapy without unnecessary changes.
  7. A 71-year-old woman (64 kg) with atrial fibrillation is stable on warfarin (goal INR 2–3) and now has a new prescription for trimethoprim-sulfamethoxazole DS 1 tablet PO BID for 7 days for cellulitis. Current medications: warfarin 5 mg PO daily, amiodarone 200 mg PO daily, lisinopril 10 mg PO daily. Labs today: INR 2.4, SCr 0.9 mg/dL, AST/ALT normal; allergies: none. Which secondary resource would best verify the clinical significance and management recommendations for the warfarin–trimethoprim/sulfamethoxazole interaction?
    Answer: Lexicomp drug interaction monograph (e.g., Lexi-Interact) for severity rating and management This question evaluates the use of secondary drug interaction resources to assess and manage potential interactions in anticoagulation therapy, highlighting tools like Lexicomp for clinical significance. The key patient-specific factor is the concurrent use of warfarin and trimethoprim-sulfamethoxazole, which can potentiate anticoagulation effects via CYP2C9 inhibition and vitamin K antagonism. Lexicomp drug interaction monograph is the best choice as it provides severity ratings (e.g., major) and management strategies like increased INR monitoring, based on compiled evidence from primary literature. AHFS Drug Information for warfarin only is suboptimal as it lacks specific interaction details with trimethoprim-sulfamethoxazole, missing comprehensive management; DailyMed package insert for trimethoprim-sulfamethoxazole only offers limited interaction data without severity grading; Natural Medicines database is incorrect for this pharmaceutical interaction, as it focuses on natural products. A transferable clinical pearl is to utilize secondary interaction checkers for rapid, evidence-based assessments in polypharmacy, ensuring patient safety through proactive monitoring. Appropriate resource selection integrates interaction severity with patient factors for tailored interventions.
  8. A 61-year-old woman (weight 68 kg) with rheumatoid arthritis takes methotrexate 20 mg PO once weekly with folic acid 1 mg PO daily; she presents with new mouth sores and nausea after starting trimethoprim-sulfamethoxazole double strength 1 tablet PO twice daily for a presumed urinary tract infection at an outside clinic. Current medications: methotrexate 20 mg weekly, folic acid 1 mg daily, celecoxib 200 mg PO daily. Allergies: none. Labs: serum creatinine 1.3 mg/dL (high), estimated creatinine clearance 45 mL/min; AST 48 U/L (high; ref 10–40), ALT 52 U/L (high; ref 7–56), white blood cell count 3.2 x103^3/mcL (low; ref 4.0–11.0). Which source provides the best evidence for managing this suspected adverse drug interaction/toxicity (including recommended interventions and monitoring)?
    Answer: Primary literature (case series/reviews) and tertiary toxicology/drug interaction references addressing methotrexate plus trimethoprim-sulfamethoxazole This question tests the selection of appropriate resources for managing a serious drug interaction causing methotrexate toxicity. The clinical scenario shows classic signs of methotrexate toxicity (mucositis, cytopenias, transaminitis) precipitated by trimethoprim-sulfamethoxazole, which inhibits folate metabolism and reduces methotrexate clearance. Primary literature and tertiary toxicology/drug interaction references (A) provide the best comprehensive evidence because they combine case reports/series documenting toxicity patterns with expert recommendations for management including leucovorin rescue, drug discontinuation, and monitoring parameters. FDA Orange Book (B) contains only therapeutic equivalence data, not toxicity management. ACLS guidelines (C) address cardiac emergencies, not drug toxicity. Outdated dosing handbooks (D) that recommend routine combination use are dangerous and contradict current evidence. The key principle is that trimethoprim-sulfamethoxazole is contraindicated with methotrexate due to dual mechanisms of toxicity: antifolate effects and reduced renal clearance. Resources addressing this interaction emphasize immediate discontinuation of TMP-SMX, high-dose leucovorin rescue, and careful monitoring of blood counts and liver function. This represents a preventable drug interaction requiring pharmacy intervention.
  9. A 68-year-old man (90 kg) with chronic gout is taking allopurinol 300 mg PO daily and presents with an acute gout flare; the prescriber orders colchicine. Medical history: stage 3 chronic kidney disease and hyperlipidemia. Current medications: allopurinol 300 mg daily, atorvastatin 40 mg daily, diltiazem ER 240 mg daily. Labs: SCr 1.8 mg/dL (CrCl ~38 mL/min), AST/ALT normal; allergies: none. Using tertiary references for renal dosing and drug interactions, which colchicine regimen is most appropriate for an acute flare in this patient?
    Answer: Colchicine 1.2 mg PO once, then 0.6 mg PO 1 hour later; avoid repeating within 3 days due to renal impairment and interacting CYP3A4/P-gp inhibitor This question examines tertiary references for renal and interaction-based dosing of colchicine in acute gout flares. The key patient-specific factor is moderate renal impairment (CrCl 38 mL/min) and concurrent diltiazem (CYP3A4/P-gp inhibitor), increasing colchicine toxicity risk. Colchicine 1.2 mg PO once then 0.6 mg 1 hour later, avoiding repeat within 3 days, is the best choice per labeling and AHFS, accounting for reduced clearance. Every hour dosing risks toxicity without limits; BID for 10 days ignores adjustments; contraindication for CrCl <60 is incorrect as adjusted use is allowed. A transferable clinical pearl is to use dosing references for cumulative adjustments in renal impairment and interactions. Resource selection prevents overdose by integrating patient factors.
  10. A 29-year-old pregnant woman (28 weeks gestation, 82 kg) presents with symptomatic urinary tract infection; urine culture is pending. Medical history: recurrent UTIs; allergies: hives to sulfonamides. Current medications: prenatal vitamin daily. Labs: SCr 0.6 mg/dL, AST/ALT normal. Based on current obstetric/infectious disease guideline recommendations, which empiric oral antibiotic is most appropriate while awaiting culture results?
    Answer: Nitrofurantoin 100 mg PO BID for 5 days This question tests guideline utilization as tertiary resources for empiric UTI treatment in pregnancy, emphasizing ACOG/IDSA recommendations. The key patient-specific factor is pregnancy (28 weeks) with sulfonamide allergy, requiring safe, effective antibiotics avoiding teratogens. Nitrofurantoin 100 mg PO BID for 5 days is the best choice per guidelines, as it's first-line for uncomplicated UTI in pregnancy with good efficacy and safety profile. Trimethoprim-sulfamethoxazole is contraindicated due to allergy and teratogenicity; ciprofloxacin risks arthropathy in fetus; doxycycline is teratogenic. A transferable clinical pearl is to reference obstetric guidelines for antimicrobial selection in special populations. Appropriate resources ensure fetal safety while treating infections effectively.
  11. A 45-year-old man (82 kg) with HIV is stable on bictegravir/emtricitabine/tenofovir alafenamide 1 tablet PO daily and starts over-the-counter St. John's wort for mood. Current medications: bictegravir/emtricitabine/tenofovir alafenamide daily, multivitamin daily, St. John's wort (self-started). Labs: HIV viral load undetectable, SCr 1.0 mg/dL, AST/ALT normal; allergies: none. Which secondary resource would best verify the interaction and provide a recommendation regarding concomitant use?
    Answer: University of Liverpool HIV drug interactions database (or equivalent HIV-specific interaction resource) This question assesses specialized secondary resources for HIV drug interactions with herbals. The key patient-specific factor is St. John's wort induction of CYP3A4/P-gp, potentially reducing bictegravir/emtricitabine/tenofovir efficacy and causing virologic failure. University of Liverpool HIV database is the best choice, recommending avoidance based on HIV-specific evidence. Red Book for pricing, irrelevant; USP <800> for handling, not interactions; Orange Book for equivalence, misapplying. A transferable clinical pearl is to use disease-focused interaction tools for antiretrovirals. Appropriate resources maintain viral suppression in complex regimens.
  12. A 56-year-old man (78 kg) with bipolar disorder is stable on lithium carbonate 900 mg/day (300 mg PO TID). He develops hypertension and is started on hydrochlorothiazide 25 mg PO daily. Current medications: lithium 300 mg TID, hydrochlorothiazide 25 mg daily, quetiapine 200 mg nightly. Labs: SCr 1.0 mg/dL, sodium 140 mEq/L, TSH normal; allergies: none. Which secondary resource would best verify the interaction and recommend monitoring and dose adjustment to prevent lithium toxicity?
    Answer: Lexicomp/Micromedex interaction database for lithium–thiazide severity, mechanism, and management This question assesses secondary interaction resources for electrolyte and pharmacokinetic effects in mood stabilizers. The key patient-specific factor is lithium with hydrochlorothiazide, where thiazides reduce lithium clearance, increasing toxicity risk. Lexicomp/Micromedex is the best choice, recommending lithium dose reduction and monitoring based on mechanism. USP <795> for compounding, irrelevant; Red Book for pricing, not applicable; CDC resources for lifestyle, misapplying. A transferable clinical pearl is to use databases for monitoring plans in narrow-index drugs. Proper resources prevent toxicity through proactive adjustments.
  13. A 67-year-old woman (66 kg) with osteoporosis is taking alendronate 70 mg PO weekly but has severe esophagitis and cannot remain upright after dosing; the health system formulary requires a substitution to an injectable option. Medical history: GERD, osteoporosis; allergies: none. Current medications: alendronate 70 mg weekly, calcium/vitamin D daily, famotidine 20 mg BID. Labs: SCr 0.9 mg/dL (CrCl 62 mL/min), calcium 9.2 mg/dL. According to tertiary references and guideline-based osteoporosis management, which formulary substitution is most appropriate?
    Answer: Denosumab 60 mg subcutaneously every 6 months This question tests tertiary references and guidelines for injectable substitutions in osteoporosis with administration challenges. The key patient-specific factor is severe esophagitis preventing oral bisphosphonate use, necessitating an injectable alternative per formulary. Denosumab 60 mg SC every 6 months is the best choice per NOF guidelines and AHFS, offering equivalent bone density benefits without GI issues. Oral ibandronate is not injectable; calcitonin is second-line with weaker efficacy; teriparatide dosing is daily, not weekly. A transferable clinical pearl is to consult guidelines for route-based therapy switches. Resource application optimizes treatment in intolerant patients.
  14. A 70-year-old man (weight 75 kg) with deep vein thrombosis is prescribed apixaban 10 mg PO twice daily for 7 days, then 5 mg PO twice daily. Current medications: phenytoin 300 mg PO nightly for seizures, amlodipine 5 mg PO daily, and omeprazole 20 mg PO daily. Allergies: none. Labs: serum creatinine 1.1 mg/dL, AST/ALT normal, hemoglobin 13.8 g/dL. Which secondary resource would best verify whether phenytoin meaningfully reduces apixaban exposure (CYP3A4/P-glycoprotein induction) and supports a management recommendation (avoidance vs alternative anticoagulant)?
    Answer: Primary literature and systematic reviews on DOAC interactions accessed via PubMed/Embase This question evaluates selecting appropriate secondary resources to assess a clinically significant drug interaction affecting anticoagulation efficacy. The concern is phenytoin's potent CYP3A4/P-glycoprotein induction potentially reducing apixaban exposure and effectiveness. Primary literature and systematic reviews accessed via PubMed/Embase (B) provide the best evidence because they offer direct access to pharmacokinetic studies, case reports of treatment failures, and expert recommendations for managing DOAC interactions with strong enzyme inducers. A general pharmacology textbook (A) provides background on CYP450 systems but lacks specific clinical data on apixaban-phenytoin interactions. USP-NF monograph (C) provides drug standards but not clinical interaction management. Consumer health websites (D) lack the scientific rigor needed for clinical decision-making. The key principle is that strong enzyme inducers like phenytoin can reduce DOAC levels by 50% or more, potentially leading to treatment failure. Secondary literature searches reveal that most experts recommend avoiding this combination entirely and using warfarin with INR monitoring instead. This evidence-based approach through secondary resources supports making definitive recommendations to prevent thrombotic complications.
  15. A 61-year-old woman (69 kg) with type 2 diabetes is prescribed semaglutide (Ozempic) and asks how to start and titrate the dose to reduce gastrointestinal adverse effects. Medical history: T2DM, obesity; allergies: none. Current medications: metformin 1000 mg PO BID, semaglutide newly prescribed. Labs: A1c 9.1%, SCr 0.8 mg/dL, AST/ALT normal. Which tertiary source provides the most appropriate dosing titration schedule for semaglutide injection for diabetes?
    Answer: FDA-approved Ozempic prescribing information for initiation (0.25 mg weekly) and titration schedule This question tests tertiary product labeling for dosing titration in GLP-1 agonists for diabetes. The key patient-specific factor is initiating semaglutide to minimize GI adverse effects in a patient with high A1c. FDA-approved Ozempic prescribing information is the best choice, recommending 0.25 mg weekly for 4 weeks, then 0.5 mg, up to 2 mg based on response. Orange Book for generics, irrelevant (none available); Sanford Guide for infections, not diabetes; USP <797> for compounding, misapplying. A transferable clinical pearl is to follow labeling for titration to improve tolerability. Resource use supports effective, patient-centered diabetes care.
  16. A 50-year-old man (102 kg) with hypertension and chronic low back pain reports new-onset ankle swelling after starting amlodipine 10 mg PO daily 6 weeks ago. Current medications: amlodipine 10 mg daily, losartan 100 mg daily, ibuprofen 400 mg PO TID PRN (uses most days). Labs: SCr 1.1 mg/dL, AST/ALT normal; allergies: none. Which source provides the best evidence for management options for amlodipine-associated peripheral edema within guideline-based hypertension therapy?
    Answer: ACC/AHA hypertension guideline and tertiary references discussing calcium channel blocker edema mitigation (e.g., dose reduction or adding ACEi/ARB) This question assesses guideline-based tertiary resources for managing adverse effects in antihypertensive therapy. The key patient-specific factor is amlodipine-induced peripheral edema in a patient with hypertension, potentially mitigated by dose adjustment or adding ACEi/ARB. ACC/AHA hypertension guidelines are the best choice, recommending strategies like adding losartan to reduce edema while maintaining BP control. Sanford Guide is for antimicrobials, irrelevant; Orange Book for equivalence, not management; Trissel's for IV, misapplying. A transferable clinical pearl is to use guidelines for adverse effect strategies in chronic therapy. Resource selection supports tolerable, effective regimens.
  17. A 60-year-old woman (76 kg) with chronic kidney disease stage 4 is prescribed gabapentin for neuropathic pain. Medical history: diabetic neuropathy, CKD; allergies: none. Current medications: insulin glargine 24 units SC nightly, insulin aspart with meals, gabapentin newly prescribed. Labs: SCr 2.9 mg/dL, creatinine clearance 18 mL/min, AST/ALT normal. Using tertiary renal dosing references, what initial gabapentin dosing is most appropriate?
    Answer: Gabapentin 300 mg PO daily with cautious titration based on response and tolerability This question examines tertiary renal dosing references for gabapentin in CKD patients with neuropathic pain. The key patient-specific factor is severe renal impairment (CrCl 18 mL/min), requiring dose reduction to avoid accumulation and sedation. Gabapentin 300 mg PO daily with cautious titration is the best choice per AHFS and labeling for CrCl <30 mL/min. 900 mg TID risks toxicity without adjustment; 600 mg every 6 hours exceeds renal capacity; 300 mg TID ignores dosing limits. A transferable clinical pearl is to apply renal references for adjusted starting doses in CKD. Resource selection prevents adverse effects in renally impaired populations.
  18. A 63-year-old man (88 kg) with heart failure with reduced ejection fraction (LVEF 30%) reports new breast tenderness and enlargement after starting spironolactone 25 mg PO daily 3 months ago. Current medications: sacubitril/valsartan 49/51 mg PO BID, carvedilol 25 mg PO BID, spironolactone 25 mg PO daily, furosemide 40 mg PO daily. Labs: K 4.7 mEq/L, SCr 1.1 mg/dL, AST/ALT normal; allergies: none. Which source provides the best evidence-based recommendation for managing spironolactone-associated gynecomastia while maintaining mortality benefit in HFrEF?
    Answer: ACC/AHA/HFSA heart failure guideline recommendations for mineralocorticoid receptor antagonist alternatives (e.g., eplerenone) This question tests the utilization of cardiology guidelines as tertiary resources for managing adverse effects in heart failure therapy, focusing on ACC/AHA/HFSA recommendations. The key patient-specific factor is spironolactone-induced gynecomastia in a male patient with HFrEF, requiring an alternative to maintain mineralocorticoid receptor antagonist benefits. ACC/AHA/HFSA heart failure guidelines are the best choice, recommending eplerenone as an alternative with lower gynecomastia risk while preserving mortality reduction. CDC immunization schedule is irrelevant for drug adverse effect management; USP monograph addresses compounding, not clinical alternatives; Sanford Guide focuses on antimicrobials, misapplying to heart failure. A transferable clinical pearl is to reference disease-specific guidelines for adverse effect mitigation, ensuring therapy optimization. Selecting appropriate tertiary resources supports evidence-based switches that balance efficacy and tolerability.
  19. A 73-year-old woman (58 kg) with hypothyroidism is stable on levothyroxine 100 mcg PO daily and starts calcium carbonate 500 mg elemental calcium PO BID for osteoporosis. Current medications: levothyroxine 100 mcg daily, calcium carbonate 500 mg elemental BID, alendronate 70 mg weekly. Labs: TSH 2.1 mIU/L (normal), SCr 0.9 mg/dL; allergies: none. Which counseling recommendation is supported by tertiary references to minimize a clinically significant interaction?
    Answer: Separate levothyroxine and calcium carbonate administration by at least 4 hours This question tests tertiary references for managing drug interactions affecting thyroid hormone absorption. The key patient-specific factor is concurrent levothyroxine and calcium carbonate, where calcium binds levothyroxine, reducing absorption and efficacy. Separating administration by at least 4 hours is the best choice per AHFS and labeling to minimize interaction. Bedtime with calcium worsens absorption; doubling dose risks hyperthyroidism; empty stomach for calcium but with food for levothyroxine inverts optimal timing. A transferable clinical pearl is to reference monographs for administration timing in absorption interactions. Appropriate resources optimize therapy adherence and efficacy.
  20. A 55-year-old woman (74 kg) with osteoarthritis requests an over-the-counter NSAID for knee pain. Medical history: peptic ulcer bleed 2 years ago, hypertension, and chronic kidney disease stage 3. Current medications: lisinopril 20 mg PO daily, hydrochlorothiazide 25 mg PO daily, pantoprazole 40 mg PO daily. Labs: SCr 1.6 mg/dL (CrCl ~42 mL/min), AST/ALT normal; allergies: none. Which tertiary resource is most appropriate to guide OTC analgesic selection and counseling considering renal and GI risk?
    Answer: AHFS Drug Information or an equivalent tertiary reference for NSAID contraindications/precautions and safer alternatives This question assesses tertiary drug information resources for OTC analgesic selection in patients with GI and renal risks. The key patient-specific factor is history of peptic ulcer bleed and CKD stage 3, contraindicating NSAIDs due to GI and renal toxicity. AHFS Drug Information is the best choice, highlighting NSAID precautions and recommending alternatives like acetaminophen. Orange Book is for equivalence, not safety; Red Book for pricing, irrelevant; ClinicalTrials.gov for trials, misapplying to counseling. A transferable clinical pearl is to consult monographs for risk-based OTC recommendations. Proper resources guide safe self-care in high-risk patients.

Start this quiz